163 related articles for article (PubMed ID: 38281751)
21. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
[TBL] [Abstract][Full Text] [Related]
23. Histiocytosis and the nervous system: from diagnosis to targeted therapies.
Cohen Aubart F; Idbaih A; Emile JF; Amoura Z; Abdel-Wahab O; Durham BH; Haroche J; Diamond EL
Neuro Oncol; 2021 Sep; 23(9):1433-1446. PubMed ID: 33993305
[TBL] [Abstract][Full Text] [Related]
24. Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases.
Pineles SL; Liu GT; Acebes X; Arruga J; Nasta S; Glaser R; Pramick M; Fogt F; Roux PL; Gausas RE
J Neuroophthalmol; 2011 Sep; 31(3):217-23. PubMed ID: 21326112
[TBL] [Abstract][Full Text] [Related]
25. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
Bonometti A; Ferrario G; Parafioriti A; Giardino D; Simonetti F; Ginori A; Passoni E; Berti E;
J Cutan Pathol; 2021 May; 48(5):637-643. PubMed ID: 33188581
[TBL] [Abstract][Full Text] [Related]
26. Neurological Manifestations of Histiocytic Disorders.
Banks SA; Sartori Valinotti JC; Go RS; Abeykoon JP; Goyal G; Young JR; Koster MJ; Vassallo R; Ryu JH; Davidge-Pitts CJ; Ravindran A; Bennani NN; Shah MV; Rech KL; Tobin WO;
Curr Neurol Neurosci Rep; 2023 Jun; 23(6):277-286. PubMed ID: 37209319
[TBL] [Abstract][Full Text] [Related]
27. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.
Durham BH; Roos-Weil D; Baillou C; Cohen-Aubart F; Yoshimi A; Miyara M; Papo M; Hélias-Rodzewicz Z; Terrones N; Ozkaya N; Dogan A; Rampal R; Urbain F; Le Fèvre L; Diamond EL; Park CY; Papo T; Charlotte F; Gorochov G; Taly V; Bernard OA; Amoura Z; Abdel-Wahab O; Lemoine FM; Haroche J; Emile JF
Blood; 2017 Jul; 130(2):176-180. PubMed ID: 28566492
[TBL] [Abstract][Full Text] [Related]
28. Langerhans Cell Histiocytosis and Other Histiocytic Diseases of the Lung.
DeMartino E; Go RS; Vassallo R
Clin Chest Med; 2016 Sep; 37(3):421-30. PubMed ID: 27514589
[TBL] [Abstract][Full Text] [Related]
29. [An overview of histiocytosis].
Tojo A
Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
[TBL] [Abstract][Full Text] [Related]
30. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
[TBL] [Abstract][Full Text] [Related]
31. Molecular and clinicopathologic characterization of pediatric histiocytoses.
Hélias-Rodzewicz Z; Donadieu J; Terrones N; Barkaoui MA; Lambilliotte A; Moshous D; Thomas C; Azarnoush S; Pasquet M; Mansuy L; Aladjidi N; Jeziorski E; Marec-Berard P; Gilibert-Yvert M; Spiegel A; Saultier P; Pellier I; Pagnier A; Pertuisel S; Poiree M; Bodet D; Millot F; Isfan F; Stephan JL; Leruste A; Rigaud C; Filhon B; Carausu L; Reguerre Y; Kieffer I; Brichard B; Ben Jannet R; Bakari M; Idbaih A; Bodemer C; Cohen-Aubart F; Haroche J; Tazi A; Boudjemaa S; Fraitag S; Emile JF; Heritier S;
Am J Hematol; 2023 Jul; 98(7):1058-1069. PubMed ID: 37115038
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary manifestations of Erdheim-Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis.
Wang JN; Wang FD; Sun J; Liang ZY; Li J; Zhou DB; Tian X; Cao XX
Br J Haematol; 2021 Sep; 194(6):1024-1033. PubMed ID: 34423426
[TBL] [Abstract][Full Text] [Related]
34. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
35. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.
Geerlinks AV; Abla O
Paediatr Drugs; 2023 Jul; 25(4):399-409. PubMed ID: 37204611
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
[TBL] [Abstract][Full Text] [Related]
38. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
Allen CE; Parsons DW
Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
[TBL] [Abstract][Full Text] [Related]
39. OCT2 expression in histiocytoses.
Ungureanu IA; Cohen-Aubart F; Héritier S; Fraitag S; Charlotte F; Lequain H; Hélias-Rodzewicz Z; Haroche J; Donadieu J; Emile JF
Virchows Arch; 2023 Jul; 483(1):81-86. PubMed ID: 36754897
[TBL] [Abstract][Full Text] [Related]
40. Identifying mutant pathways in the histiocytoses.
Prince HM
Blood; 2014 Nov; 124(19):2901-3. PubMed ID: 25377560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
